Lantheus (LNTH) Stock Price, News & Analysis

Company Overview

Lantheus Holdings, Inc. (NASDAQ: LNTH) is a healthcare company that develops, manufactures and commercializes diagnostic and therapeutic products, with a focus on medical imaging and radiopharmaceuticals. Its products are used by physicians and healthcare providers to help detect, characterize and monitor disease.

The company’s portfolio includes PYLARIFY (piflufolastat F 18), a positron emission tomography imaging agent used to identify prostate-specific membrane antigen-positive lesions in men with prostate cancer, and DEFINITY, an ultrasound-enhancing agent used to improve cardiac ultrasound imaging. Lantheus also offers radiopharmaceutical products and related imaging solutions used in nuclear medicine and other diagnostic procedures.

Lantheus serves hospitals, imaging centers, clinics and other healthcare providers, primarily in the United States, while also maintaining international commercial and development activities. The company traces its roots to the development and commercialization of medical imaging products and is headquartered in North Billerica, Massachusetts.

Key Stats

• Today's Range: $99.52 to $99.79
• 50-Day Range: $99.51 to $108.03
• 52-Week Range: $49.67 to $111.86
• Volume: 505,558 shs
• Average Volume: 982,694 shs
• Market Capitalization: $6.50 billion
• P/E Ratio: 24.07
• Dividend Yield: N/A
• Price Target: $108.11
• Consensus Rating: Hold

Lantheus Stock Analysis - MarketRank™

Lantheus scored higher than 64% of companies evaluated by MarketBeat, and ranked 304th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.8 / 5
• Analyst Rating: Hold

Consensus Rating

Lantheus has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on no strong buy ratings, 4 buy ratings, 10 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Lantheus is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Lantheus has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 21.33%

Earnings Growth

Earnings for Lantheus are expected to grow by 21.33% in the coming year, from $4.50 to $5.46 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lantheus is 24.07, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.80.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lantheus is 24.07, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 272.65.

Price to Book Value per Share Ratio

Lantheus has a P/B Ratio of 6.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.29% of the float of Lantheus has been sold short.

Short Interest Ratio / Days to Cover

Lantheus has a short interest ratio ("days to cover") of 4.07.

Change versus previous month

Short interest in Lantheus has recently decreased by 4.72%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lantheus does not currently pay a dividend.

Dividend Growth

Lantheus does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.24

News Sentiment

Lantheus has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for Lantheus this week, compared to 8 articles on an average week.

MarketBeat Follows

4 people have added Lantheus to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lantheus insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.70% of the stock of Lantheus is held by insiders.

Percentage Held by Institutions

99.06% of the stock of Lantheus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/02/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:LNTH
• CIK: 1521036
• Web: www.lantheus.com
• Phone: (978) 671-8001
• Fax: 978-671-8860
• Employees: 1,193
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Lantheus: $108.11
• High Price Target: $129.00
• Low Price Target: $94.00
• Potential Upside/Downside: +8.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.29
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): $4.14
• Trailing P/E Ratio: 24.07
• Forward P/E Ratio: 22.14
• P/E Growth: N/A
• Net Income: $233.56 million
• Net Margins: 17.69%
• Pretax Margin: 23.32%
• Return on Equity: 28.10%
• Return on Assets: 14.35%

Debt

• Debt-to-Equity Ratio: 0.43
• Current Ratio: 3.06
• Quick Ratio: 2.89

Sales & Book Value

• Annual Sales: $1.54 billion
• Price / Sales: 4.22
• Cash Flow: $6.39 per share
• Price / Cash Flow: 15.59
• Book Value: $16.43 per share
• Price / Book: 6.07

Miscellaneous

• Outstanding Shares: 65,270,000
• Free Float: 64,162,000
• Market Cap: $6.50 billion
• Optionable: Optionable
• Beta: -0.06